SOPHiA GENETICS (NASDAQ:SOPH) Insider Manuela Valente Sells 2,597 Shares

SOPHiA GENETICS SA (NASDAQ:SOPH) insider Manuela Valente sold 2,597 shares of the business’s stock in a transaction on Monday, April 6th. The stock was sold at an average price of $4.85, for a total value of $12,595.45. Following the transaction, the insider directly owned 221,651 shares of the company’s stock, valued at $1,075,007.35. The trade was a 1.16% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Manuela Valente also recently made the following trade(s):

• On Tuesday, April 7th, Manuela Valente sold 2,376 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.87, for a total value of $11,571.12.
• On Thursday, March 19th, Manuela Valente sold 380 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.79, for a total value of $1,820.20.

SOPHiA GENETICS Trading Down 0.8%

NASDAQ:SOPH opened at $4.86 on Thursday. The stock has a 50-day simple moving average of $4.77 and a 200-day simple moving average of $4.68. The stock has a market cap of $332.86 million, a P/E ratio of -9.53 and a beta of 1.04. SOPHiA GENETICS SA has a 1 year low of $2.58 and a 1 year high of $5.70. The company has a debt-to-equity ratio of 1.01, a quick ratio of 1.84 and a current ratio of 1.96.

SOPHiA GENETICS (NASDAQ:SOPH) last released its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.08). The business had revenue of $21.71 million for the quarter, compared to analyst estimates of $21.20 million. SOPHiA GENETICS had a negative return on equity of 50.60% and a negative net margin of 44.22%. As a group, analysts anticipate that SOPHiA GENETICS SA will post -0.96 earnings per share for the current fiscal year.

Institutional Trading of SOPHiA GENETICS

Large investors have recently made changes to their positions in the company. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in shares of SOPHiA GENETICS by 246.9% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,632,871 shares of the company’s stock valued at $25,341,000 after acquiring an additional 5,432,871 shares during the period. Federated Hermes Inc. raised its position in SOPHiA GENETICS by 16.4% in the 2nd quarter. Federated Hermes Inc. now owns 220,000 shares of the company’s stock valued at $682,000 after purchasing an additional 31,000 shares during the last quarter. Akre Capital Management LLC raised its position in SOPHiA GENETICS by 66.2% in the 2nd quarter. Akre Capital Management LLC now owns 3,719,140 shares of the company’s stock valued at $11,529,000 after purchasing an additional 1,481,636 shares during the last quarter. Alta Wealth Advisors LLC purchased a new stake in SOPHiA GENETICS in the 3rd quarter valued at $6,708,000. Finally, Savvy Advisors Inc. purchased a new stake in SOPHiA GENETICS in the 3rd quarter valued at $48,000. 31.59% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms have recently issued reports on SOPH. Guggenheim upped their price objective on SOPHiA GENETICS from $6.00 to $7.00 and gave the stock a “buy” rating in a research report on Monday, January 26th. BTIG Research reaffirmed a “buy” rating and set a $7.00 price objective on shares of SOPHiA GENETICS in a research report on Tuesday, March 3rd. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SOPHiA GENETICS in a research report on Thursday, January 22nd. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, SOPHiA GENETICS presently has a consensus rating of “Hold” and a consensus target price of $7.00.

Key Stories Impacting SOPHiA GENETICS

Here are the key news stories impacting SOPHiA GENETICS this week:

• Neutral Sentiment: CEO Jurgi Camblong executed two Rule 10b5‑1 sales (2,600 and 2,500 shares at ~$4.85–4.86). CEO still holds ~3.7M shares. SEC filing
• Neutral Sentiment: CFO George Cardoza reported multiple small sales (~2,520; 2,413 shares) under a 10b5‑1 plan to cover taxes; remaining holdings stay large (~292–295k shares). SEC filing
• Neutral Sentiment: CTO Abhimanyu Verma sold several tranches (2,519; 1,030 shares) under a 10b5‑1 plan; still owns ~204–205k shares. SEC filing
• Neutral Sentiment: President Ross Muken and other senior managers (Philippe Menu, Zhenyu Xu, Manuela Valente, Well Daan Van, Kevin Puylaert) reported multiple planned sales of ~600–2,700 shares each to cover tax obligations; each filing cites Rule 10b5‑1 plans. Representative filings: Menu, Xu, Valente. Menu SEC filing
• Neutral Sentiment: Collectively the insider sales are modest relative to total insider holdings and were executed under pre‑arranged plans (tax withholding stated as purpose), which reduces negative informational signal but can still create short-term selling pressure.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.